TrialsgrambetaRCTs are beautiful

FIGARO-DKD

2021

Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease

In 7,437 patients with type 2 diabetes and CKD, finerenone reduced the cardiovascular composite compared with placebo.

Result

Efficacy: CV death, MI, stroke or HF hospitalisationHR 0.87 (95% CI 0.76-0.98) · P = 0.03

Below 1 favours finerenone, above 1 favours placebo.

Event rates
Absolute difference
1.8 points
NNT
56

Absolute difference and NNT are derived from the event rates.

Original publication
Subtopic
Nonsteroidal MRA
Design
Double-blind RCT, median 3.4-year follow-up
Relevance
Important: one of several pillars.
Source
Pitt B, et al. N Engl J Med. 2021;385(24):2252-2263.doi 10.1056/NEJMoa2110956

Discussion & critique

Confirmed the cardiovascular benefit of finerenone across the milder end of the CKD spectrum; pooled with FIDELIO in the FIDELITY analysis.

Discussed in podcasts